-
公开(公告)号：US20110166095A1
公开(公告)日：2011-07-07
申请号：US12975970
申请日：2010-12-22
IPC分类号： A61K31/7064 , C12Q1/02 , C40B30/06 , A61P35/00
CPC分类号： G01N33/57449 , G01N33/57484 , G01N2800/52
摘要： The phosphorylation status of the BAD protein is a determinant of ovarian cancer cell responsiveness to platinum chemotherapy. Indirect manipulation of BAD phosphorylation status influences cisplatin sensitivity. BAD phosphorylation represents a biomarker that predicts platinum sensitivity and is a therapeutic target to increase platinum sensitivity. The methods employ phospho-specific antibody against a particular amino acid residue or site. Phospho-specific protein characterization methods include immunohistochemical (IHC), flow cytometric, immunofluorescent, capture-and-detection, or reversed phase assay.
摘要翻译： BAD蛋白的磷酸化状态是卵巢癌细胞对铂化疗反应的决定因素。 间接操作BAD磷酸化状态影响顺铂敏感性。 BAD磷酸化代表了预测铂敏感性的生物标志物，并且是增加铂敏感性的治疗靶标。 该方法使用针对特定氨基酸残基或位点的磷酸特异性抗体。 磷酸特异性蛋白质表征方法包括免疫组织化学（IHC），流式细胞术，免疫荧光，捕获和检测或反相测定。
-
公开(公告)号：US09063143B2
公开(公告)日：2015-06-23
申请号：US12975970
申请日：2010-12-22
IPC分类号： G01N33/53 , G01N33/574
CPC分类号： G01N33/57449 , G01N33/57484 , G01N2800/52
摘要： The phosphorylation status of the BAD protein is a determinant of ovarian cancer cell responsiveness to platinum chemotherapy. Indirect manipulation of BAD phosphorylation status influences cisplatin sensitivity. BAD phosphorylation represents a biomarker that predicts platinum sensitivity and is a therapeutic target to increase platinum sensitivity. The methods employ phospho-specific antibody against a particular amino acid residue or site. Phospho-specific protein characterization methods include immunohistochemical (IHC), flow cytometric, immunofluorescent, capture-and-detection, or reversed phase assay.
摘要翻译： BAD蛋白的磷酸化状态是卵巢癌细胞对铂化疗反应的决定因素。 间接操作BAD磷酸化状态影响顺铂敏感性。 BAD磷酸化代表了预测铂敏感性的生物标志物，并且是增加铂敏感性的治疗靶标。 该方法使用针对特定氨基酸残基或位点的磷酸特异性抗体。 磷酸特异性蛋白质表征方法包括免疫组织化学（IHC），流式细胞术，免疫荧光，捕获和检测或反相测定。
-
搜索结果
2 条记录 (耗时 0.023 秒)
